ADMA Biologics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2013. The filing is an annual report, although the requested period is identified as 2013 Q4. ADMA is a late-stage biopharmaceutical company developing plasma-derived biologics, principally RI-002, and operates an FDA-licensed, GHA-certified plasma collection center in Georgia.
Business Context and Development Status
- RI-002 is an RSV-antibody-enriched intravenous immune globulin being developed initially for primary immunodeficiency disease.
- The pivotal Phase III trial began enrolling in February 2013 and completed enrollment in October 2013; 59 patients were enrolled at nine U.S. treatment centers.
- Management expected preliminary Phase III data in the fourth quarter of 2014, a Biologics License Application submission in the first half of 2015, and potential first commercial sales as early as the first half of 2016, subject to successful results and FDA approval.
- Current product revenue is derived from plasma sales and plasma-derived medicinal products; the company has not generated revenue from RI-002 therapeutics.
Financial Performance and Position
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Total revenue | $3.068 million | $1.118 million | Up $1.949 million |
| Product revenue | $3.024 million | $1.118 million | Up $1.905 million |
| License revenue | $44,074 | — | New in 2013 |
| Cost of product revenue | $2.023 million | $669,056 | Up $1.354 million |
| Gross profit | $1.044 million | $449,062 | Up $595,074 |
| Research and development | $9.303 million | $3.469 million | Up $5.834 million |
| Operating loss | $15.042 million | $7.909 million | Loss increased $7.133 million |
| Net loss | $15.527 million | $7.301 million | Loss increased $8.226 million |
| Net loss per share | $2.38 | $1.39 | Loss per share increased |
| Net cash used in operations | $10.887 million | $6.904 million | Use increased $3.983 million |
- Margins: Gross margin was approximately 34.0% in 2013 versus 40.1% in 2012. Operating margin was approximately negative 490.3%, and net margin was approximately negative 506.3% in 2013.
- Cash and liquidity: At December 31, 2013, cash and cash equivalents were $26.149 million, short-term investments were $2.935 million, and working capital was approximately $27.4 million.
- Debt: Balance-sheet debt included $4.865 million of notes payable, $132,500 of end-of-term liability, and $77,890 of leasehold improvement debt. The Hercules facility was subsequently amended on February 24, 2014, increasing potential borrowing capacity to $15 million, including an additional $5 million contingent on Phase III results supporting a BLA filing.
- Financing: The October 2013 IPO generated approximately $26.6 million of net proceeds. Financing activities provided $27.633 million of cash in 2013.
- Capital structure: Shares outstanding increased to 9,291,823 at December 31, 2013 from 5,871,002 at December 31, 2012. Accumulated deficit was $52.637 million.
Material Changes Versus 2012
- Revenue increased primarily because of higher plasma collections, donor recruitment, and additional collection equipment.
- R&D spending increased substantially as the Phase III trial reached full enrollment and manufacturing, testing, and regulatory activities expanded.
- Plasma center expenses and general and administrative expenses increased with higher collection activity, stock-based compensation, professional fees, and public-company costs.
- Interest expense increased to $618,225 from $30,683, largely because of the Hercules debt, debt discount amortization, and deferred financing costs.
- The company completed its IPO and reclassified the Hercules warrant liability to additional paid-in capital after the IPO eliminated the down-round protection feature.
- Deferred revenue of $1.7 million was recorded for services under the Biotest license agreement and is being recognized over approximately 20 years.
Guidance, Outlook, Risks, and Unusual Items
- Management expected available cash, short-term investments, operating revenue, and available Hercules funding to support operations into 2016, but stated that additional capital may be needed earlier if assumptions are incorrect.
- The company expects R&D and general and administrative expenses to increase in 2014 as Phase III activities, regulatory work, hiring, and plasma-center expansion continue.
- ADMA depends substantially on Biotest: substantially all revenue was attributed to one customer, and Biotest is also a key plasma supplier, manufacturing partner, and licensee.
- RI-002 is the only product candidate in clinical development. Failure of the Phase III trial or FDA review would leave plasma collection and sales as the company’s principal revenue source.
- The company relies on third-party manufacturers and suppliers and does not own issued patents; protection of its technology depends primarily on trade secrets and confidentiality agreements.
- Plasma collection, manufacturing, contamination, transmissible disease, regulatory compliance, reimbursement, product liability, and clinical-trial execution are significant risks.
- The Hercules debt is secured by substantially all company assets other than intellectual property, which is subject to a negative pledge. Defaults could permit acceleration and disposition of collateral.
- Long-term leases for the Norcross and Marietta plasma facilities represented approximately $3.556 million of future minimum payments as disclosed in the filing.
- The company reported no material pending legal proceedings. Management concluded that disclosure controls and internal control over financial reporting were effective, although the auditor was not required to provide an internal-control attestation.
Investor Verification Checklist
- Verify final Phase III RI-002 results, BLA submission timing, FDA acceptance, and approval status against the projected 2014–2016 milestones.
- Assess cash burn, remaining Hercules borrowing availability, debt repayment obligations beginning in 2015, and the timing and terms of any additional financing.
- Review revenue concentration and the status of Biotest supply, manufacturing, licensing, royalty, and customer arrangements.
- Confirm licensing and operating status of the Marietta plasma center and the company’s ability to expand plasma collections while maintaining FDA and GHA compliance.
- Evaluate whether plasma sales can fund operations before RI-002 commercialization and whether gross margins remain adequate as collection volumes grow.
- Review dilution from outstanding options and warrants, including approximately 1.0 million potentially dilutive securities at December 31, 2013.
- Consider the company’s accumulated deficit, continuing negative operating cash flow, lack of approved commercial therapeutics, and dependence on future capital access.